Orphan drug legislation: lessons for neglected tropical diseases-Reference-Cited by-同舟云学术

Orphan drug legislation: lessons for neglected tropical diseases

Published:2009-01 Issue:1 Volume:24 Page:27-42
ISSN:0749-6753
Container-title:The International Journal of Health Planning and Management
language:en
Short-container-title:Int. J. Health Plann. Mgmt.

Author:

Villa Stefano,Compagni Amelia,Reich Michael R.

Publisher

Wiley

Subject

Health Policy

Reference39 articles.

1. The DOHA declaration on the TRIPS agreement and public health: lighting a dark corner at the WT;Abbott;J Int Econ Law,2002

2. Alcimed. 2005. Study on orphan drugs. Considerations on the application of Article 8.2 of EC Regulation no. 141/2000 concerning orphan drugs. http://pharmacos.eudra.org/F2/orphanmp/doc/pricestudy/Final%20final%20report%20part%202%20web.pdf2005 (last accessed 28 January 2008).

3. Rare diseases, drug development, and AIDS: the impact of the Orphan Drug Act;Arno;Milbank Q,1995

4. Vaccine advance-purchase agreements for low-income countries: practical issues;Berndt;Health Aff,2005

5. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates;Berndt;Nat Rev Drug Discov,2005

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010–2019: a cross-sectional analysis;BMJ Open;2024-03

2. Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration 2010–2019;2023-06-04

3. Cancer in sub-Saharan Africa: a Lancet Oncology Commission;The Lancet Oncology;2022-06

4. Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review;The Lancet Regional Health - Europe;2021-10

5. Chagas Congenital Screening in Switzerland: Processes of Recognition and Knowledge-Sharing;Medical Anthropology;2021-05-28